Introduction
Apoptosis, the cell's intrinsic death program, plays a crucial role in the regulation of tissue homeostasis, and an imbalance between cell death and proliferation may result in tumor formation (Lowe and Lin, 2000) . Also, killing of tumor cells by diverse cytotoxic approaches such as anticancer drugs, g-irradiation, suicide genes or immunotherapy, is predominantly mediated through induction of apoptosis in tumor cells (Fulda et al., , 2001 (Fulda et al., , 2002 Hengartner, 2000; Kaufmann and Earnshaw, 2000; Herr and Debatin, 2001; Debatin et al., 2002; Johnstone et al., 2002) . Apoptosis pathways may be initiated through different entry sites, for example, at the cell surface or through mitochondria resulting in activation of effector caspases (Hengartner, 2000) . Triggering of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO-1/Fas) or TNF-related apoptosis-inducing ligand (TRAIL) receptors at the cell surface results in caspase-8 activation which initiates direct cleavage of downstream effector caspases (Ashkenazi and Dixit, 1998; Scaffidi et al., 1998; Thornberry and Lazebnik, 1998; Walczak and Krammer, 2000) . The mitochondrial pathway is initiated by the release of apoptogenic factors such as cytochrome c, apoptosis-inducing factor (AIF), second mitochondria-derived activator of caspase (Smac)/DIABLO or endonuclease G from mitochondria into the cytosol triggering caspase-3 activation as a result of formation of the cytochrome c/Apaf-1/ caspase-9-containing apoptosome complex (Kroemer and Reed, 2000; van Loo et al., 2002) .
Based on the concept that anticancer therapy primarily act by inducing cell death, defects in apoptosis programs may contribute to tumor progression and treatment resistance (Cory and Adams, 2002; Igney and Krammer, 2002) . Defective apoptosis signaling may be caused by increased expression of antiapoptotic molecules or by impaired function of proapoptotic molecules (Igney and Krammer, 2002) . Inhibitor of apoptosis proteins (IAPs) such as survivin are expressed at high levels in many tumors and have been associated with refractory disease and poor prognosis (Salvesen and Duckett, 2002; Altieri, 2003) . Inhibition of effector caspases by IAPs occurs at the core of the apoptotic machinery. Thus, therapeutic modulation of IAPs could target a key control point in cancer resistance (Goyal, 2001) .
In recent years, naturally occurring antioxidant compounds present in diet and beverages consumed by humans such as resveratrol have gained considerable attention because of their beneficial effects on health as cancer chemopreventive or cardioprotective agents (Park and Pezzuto, 2002) . Resveratrol (3, 4 0 ,5-trihydroxystilbene) is a polyphenol synthesized by a variety of plant species and is present in grapes or in red wine (Cal et al., 2003) . In addition to its canceropreventive and cardioprotective properties, some reports have also suggested a direct antitumor activity (Gusman et al., 2001) .
In search for novel strategies to overcome resistance of tumor cells, we tested the antitumor activities of resveratrol on human tumor cell lines in the present study. We found that resveratrol is a potent sensitizer for anticancer drug-induced apoptosis in a variety of human tumor cell lines by inducing cell cycle arrest and survivin depletion in a p53-independent manner.
Results
Naturally occurring dietary compounds such as resveratrol have gained considerable attention as cancer preventive agents. In search for novel strategies to overcome resistance of tumors, we tested the antitumor activities of resveratrol on human tumor cell lines in the present study.
Sensitization for drug-induced apoptosis by resveratrol
To test the antitumor activity of resveratrol, we initially selected SHEP neuroblastoma cells that have been previously proven suitable for studies on drug-induced apoptosis Kim and Feldman, 2002) . Incubation of SHEP neuroblastoma cells with resveratrol resulted in strong inhibition of proliferation in a dose-and time-dependent manner (Figure 1a and b) . Interestingly, resveratrol only moderately induced apoptosis at concentrations, which strongly inhibited proliferation ( Figure 1c ). This indicates that the cytostatic activity of resveratrol was more pronounced than its cytotoxic activity at equimolar concentrations in SHEP neuroblastoma cells.
Given the relatively low cytotoxic activity of resveratrol as single agent we then tested resveratrol in combination with conventional cytotoxic drugs. Interestingly, we found that pretreatment with resveratrol cooperated with anticancer agents, for example, VP16, doxorubicin, cytarabine (AraC), actinomycin D, taxol or methotrexate to induce apoptosis in SHEP neuroblastoma cells in a dose-and time-dependent manner (Figure 2a-g ). Dose response experiments revealed that a concentration of 30 mM resveratrol was similarly effective compared to 100 mM resveratrol to sensitize SHEP neuroblastoma cells for AraC or taxol-induced apoptosis (Figure 2h ). Also, resveratrol cooperated with cytotoxic drugs to inhibit clonogenic tumor cell growth (Figure 2i ). Since a combination of cytotoxic agents may give rise to different effects depending on timing during a fixed treatment schedule, we tested whether the sequence of treatment with resveratrol and anticancer agents might influence the cooperative effect. Interestingly, sequential treatment with resveratrol followed by cytotoxic drugs yielded more apoptosis than cotreatment with resveratrol and drugs (Figure 2j ). Treatment with the reversed sequence of cytotoxic drugs followed by resveratrol was significantly less effective than treatment with resveratrol followed by cytotoxic drugs or cotreatment with both compounds and only slightly more effective than treatment with either cytotoxic drugs or resveratrol alone (Figure 2j ). These findings Figure 1 Effect of resveratrol on proliferation and apoptosis. SHEP neuroblastoma cells were treated with 0-100 mM resveratrol for indicated times. Cell count (a) was determined by cell counter, proliferation (b) was determined by assessing the number of BrdUstained cells and apoptosis (c) was determined by FACS analysis of propidium iodide-stained DNA as described in Materials and methods. Percentage of proliferation was determined as (proliferation of treated cells Â 100/proliferation of untreated cells) Sensitization for drug-induced apoptosis by resveratrol S Fulda and K-M Debatin indicate that pretreatment with resveratrol conferred a state of increased responsiveness to drug-induced apoptosis.
To see whether sensitization by resveratrol involved caspases, we analysed activation of caspases by Western blot analysis. Treatment of SHEP neuroblastoma cells with AraC resulted in enhanced cleavage of caspase-3, caspase-8 and PARP indicating that resveratrol cooperated with AraC to activate caspases (Figure 2k ).
Sensitization for drug-induced apoptosis through resveratrol-mediated cell cycle arrest
Since differential sensitivity to apoptosis has been linked to distinct phases of the cell cycle (Pucci et al., 2000;  (a-h) Effect of resveratrol on drug-induced apoptosis. SHEP neuroblastoma cells were cultured in medium (white bars) or were pretreated for 24 h with 30 mM resveratrol (black bars), followed by treatment with 0-0.1 mg/ml doxorubicin for 24 h (a) or 48h, (b) 0-3 mg/ml VP16, (c) 0-1 mg/ml cytarabine (AraC), (d) 0-10 nM taxol (e), 0-30 ng/ml actinomycin D, (f) or 0-10 mg/ml methotrexate (g). In (h), SHEP neuroblastoma cells were pretreated for 24 h with 0-100 mM resveratrol, followed by treatment for 24 h with 1 mg/ml AraC or 10 nM taxol. Apoptosis was assessed by FACS analysis of propidium iodidestained DNA. (i) Effect of resveratrol on drug-induced clonogenic survival. SHEP neuroblastoma cells were treated with 0-0.3 mg/ml VP16, 0.1 mg/ml AraC or 0.01 mg/ml doxorubicin in the presence ( þ Res) or absence (ÀRes) of 30 mM resveratrol. Clonogenic survival was assessed by crystal violet staining after 7 days and colony numbers per well of a 24-well plate are indicated. (j) Sequence-dependent effect of resveratrol on drug-induced apoptosis. SHEP neuroblastoma cells were left untreated (no Tx) or were treated with 30 mM resveratrol for 24 h (res), 0.1 mg/ml doxorubicin for 24 h (Dox), 3 mg/ml VP16 for 24 h (VP16), 1 mg/ml AraC for 24 h (AraC), 30 mM resveratrol for 24 h followed by 0.1 mg/ml doxorubicin for 24 h (ResÀDox), 30 mM resveratrol for 24 h followed by 3 mg/ml VP16 for 24 h (ResÀVP16), 30 mM resveratrol for 24 h followed by 1 mg/ml AraC for 24 h (ResÀAraC), 30 mM resveratrol and 0.1 mg/ml doxorubicin for 24 h (Res þ Dox), 30 mM resveratrol and 3 mg/ml VP16 for 24 h (Res þ VP16), 30 mM resveratrol and 1 mg/ml AraC for 24 h (Res þ AraC), 0.1 mg/ml doxorubicin for 24 h followed by 30 mM resveratrol for 24 h (Dox-Res), 3 mg/ml VP16 for 24 h followed by 30 mM resveratrol for 24 h (VP16ÀRes) or 1 mg/ml AraC for 24 h followed by 30 mM resveratrol for 24 h (AraCÀRes). Apoptosis was assessed by FACS analysis of propidium iodide-stained DNA. (k) Effect of resveratrol on AraC-induced caspase activation. SHEP neuroblastoma cells were treated with 30 mM resveratrol and/or 1 mg/ml AraC for 24 h. Expression of caspaseÀ3, À8, À9, PARP and b-actin was assessed by Western blot analysis Sensitization for drug-induced apoptosis by resveratrol S Fulda and K-M Debatin Smith et al., 2000) , we then analysed in more detail the effect of resveratrol on cell cycle. Cell cycle analysis revealed accumulation of cells in S phase upon treatment with 30 mM resveratrol ( Figure 3a ). We then tested whether resveratrol-mediated arrest in S phase was a prerequisite for apoptosis induction. Cells were double stained with propidium iodide for cell cycle analysis and with annexin V for determination of apoptosis and analysed by flow cytometry. Treatment with resveratrol alone resulted in accumulation of cells in S phase without induction of apoptosis ( Figure 3b ). Also, treatment with AraC alone did not induce apoptosis ( Figure 3b ). Importantly, pretreatment with resveratrol followed by treatment with AraC resulted in apoptosis preferentially in cells arrested in S phase ( Figure 3b ). These findings indicate that resveratrol-induced cell cycle arrest in S phase sensitized for treatment with AraC.
To directly test the sensitivity at different phases of the cell cycle, cells were arrested in G1, S or G2 phase using the specific cell cycle inhibitors mimosine, thymidine or nocodazole, and then treated with cytotoxic drugs. Arresting cells in S or G1 phase by thymidine or mimosine (data not shown) sensitized cells for subsequent treatment with cytotoxic drugs, whereas no sensitization for drug treatment was found when cells were arrested in G2 by nocodazole ( Figure 3c ). Similarly, cell cycle arrest in S phase using hydroxyurea or aphidicolin (data not shown), an inhibitor of DNA polymerase, enhanced drug-induced apoptosis ( Figure 3c ). These findings indicate a differential sensitivity for drug-induced apoptosis at different phases of the cell cycle with increased sensitivity in S or G1 phase. Similar to treatment with resveratrol, sequential treatment with thymidine, hydroxyurea or aphidicolin followed by cytotoxic drugs yielded more apoptosis than cotreatment with these agents or treatment with the reversed sequence of cytotoxic drugs followed by cell cycle inhibitors (data not shown).
Modulation of apoptosis regulatory molecules by resveratrol
To gain further insight into the molecular mechanism(s) linking cell cycle regulation and apoptosis sensitivity upon treatment with resveratrol, we investigated several key molecules known to regulate apoptosis. Treatment with resveratrol resulted in upregulation of p53 and p21 Effect of resveratrol on cell cycle and apoptosis. SHEP neuroblastoma cells were left untreated (no Tx) or were treated for 24 h with 30 mM resveratrol (Res) or 1 mg/ml AraC (AraC) or with 30 mM resveratrol for 24 h followed by 1 mg/ml AraC for 24 h (ResÀAraC). Concomitant analysis of cell cycle and apoptosis was performed by staining with propidium iodide (PI, x-axis) and annexin-FITC (y-axis) as described in Materials and methods. The percentage of cells in each quadrant are indicated (lower left: G1 phase-annexin low, lower right: S/G2/M phase-annexin low, upper left: G1 phase-annexin high, upper right: S/G2/M phase-annexin high). (c) Effect of cell cycle inhibitors on drug-induced apoptosis. SHEP neuroblastoma cells were cultured in medium or were pretreated for 24 h with 2 mM thymidine, 0.4 mM mimosine, 0.4 mg/ml nocodazole, 20 mM hydroxyurea or 0.3 mg/ml aphidicolin and further cultured for 24 h with 0.1 mg/ml doxorubicin, 3 mg/ml VP16 or 1 mg/ml AraC. Apoptosis was assessed by FACS analysis of propidium iodide-stained DNA Sensitization for drug-induced apoptosis by resveratrol S Fulda and K-M Debatin protein expression as well as strong downregulation of survivin, an 'inhibitor of apoptosis protein' (IAP) (Figure 4 ). In contrast, expression levels of other IAP family members such as XIAP, cIAP1 or cIAP2 or expression of Bcl-2 family proteins such as Bcl-2, Bax or Bcl-X L were not substantially altered by treatment with resveratrol ( Figure 4 ). Interestingly, resveratrol had no detectable effect on FLIP expression (Figure 4) , a labile inhibitor of apoptosis, which we previously found to be rapidly downregulated by protein synthesis inhibitors (Fulda et al., 2000) . Also, no upregulation of CD95 ligand, TRAIL or surface expression of CD95 or agonistic TRAIL receptors was found (data not shown). In addition, treatment of SHEP neuroblastoma cells with mimosine, thymidine, hydroxyurea or aphidicolin resulted in reduction of survivin protein expression (data not shown) consistent with cell cycle dependence of survivin expression (Altieri, 2002) .
p53-independent downregulation of survivin and sensitization for drug-induced apoptosis by resveratrol p53 has been implicated in regulation of both cell cycle and apoptosis (Pucci et al., 2000; Smith et al., 2000) . Since resveratrol treatment resulted in induction of p53 protein (Figure 4) , we asked whether p53 may provide a molecular link between resveratrol-induced cell cycle alterations and apoptosis. To address this question, we inhibited p53 function using the p53 inhibitor pifithrin-a in SHEP neuroblastoma cells, which harbor wild-type p53. Interestingly, preincubation of SHEP neuroblastoma cells with pifithrin-a, which reduced resveratrolinduced p53 expression (data not shown), did not block resveratrol-mediated sensitization for cytotoxic drugs, for example, AraC, actinomycin D or VP16 (Figure 5a ). Next, we used wild-type p53 and p53-deficient HCT116 colon carcinoma cells. Pretreatment of wild-type p53 HCT116 colon carcinoma with resveratrol, which resulted in accumulation of p53 protein (data not shown), markedly enhanced 5-fluorouracil (5-FU)-induced apoptosis (Figure 5b) . Importantly, pretreatment with resveratrol also sensitized p53-deficient HCT116 colon carcinoma cells, which were resistant towards treatment with 5-FU in the absence of resveratrol (Figure 5c ). Interestingly, cell cycle arrest and associated Figure 4 Effect of resveratrol on apoptosis regulatory molecules. SHEP neuroblastoma cells were treated with 30 mM resveratrol for 0-48 h and assessed for protein expression of p53, p21, survivin, XIAP, cIAP1, cIAP2, Bcl-2, Bax, Bak, Bcl-X L and FLIP by Western blot analysis. Expression of b-actin was used to control for equal gel loading. In addition to XIAP, a nonspecific XIAP immune-reactive molecule migrating slightly larger than XIAP was detected using the mouse monoclonal antibody H62120 (Deveraux and Reed, 1999), which is indicated by asterix Figure 5 Sensitization for drug-induced apoptosis by resveratrol independent of p53 status. (a) Effect of the p53 inhibitor pifithrin-a on resveratrol-mediated sensitization for drug-induced apoptosis. SHEP neuroblastoma cells were left untreated or were pretreated for 24 h with 30 mM resveratrol and/or 30 mM pifithrin-a and treated with 0.3 mg/ml AraC, 30 ng/ml actinomycin D (ActD) or 3 mg/ml VP16 for 24 h. Apoptosis was assessed by FACS analysis of propidium iodide-stained DNA. (b, c) Effect of resveratrol on 5-FU-induced apoptosis in p53-deficient colon carcinoma cells. Wildtype p53 (b) or p53-deficient (c) HCT116 colon carcinoma cells were cultured in medium (white bars) or were pretreated for 24 h with 30 mM resveratrol (black bars), followed by treatment for 24 h with 0-100 mM 5-FU. Apoptosis was assessed as by FACS analysis of propidium iodide-stained DNA Sensitization for drug-induced apoptosis by resveratrol S Fulda and K-M Debatin downregulation of survivin protein expression upon treatment with resveratrol was found in both wild-type p53 and p53-deficient HCT116 colon carcinoma cells (data not shown). These findings indicate that cell cycle arrest, downregulation of survivin expression and sensitization for drug-induced apoptosis by resveratrol did not depend on wild-type p53 function.
Downregulation of survivin by resveratrol sensitizes for drug-induced apoptosis
We then analysed in more detail the involvement of survivin in resveratrol-mediated sensitization. Treatment with resveratrol resulted in reduction of survivin mRNA expression (Figure 6a ) indicating that survivin expression was regulated by resveratrol at the transcriptional level. To investigate whether survivin expression was regulated by resveratrol also at the post-transcriptional level, we used the proteasome inhibitor lactacystin. Interestingly, downregulation of survivin protein levels upon treatment with resveratrol was inhibited in the presence of the proteasome inhibitor lactacystin (Figure 6b ), which did not prevent resveratrol-induced cell cycle arrest and did not trigger apoptosis in the tested conditions (data not shown). Likewise, inhibition of protein synthesis by cycloheximide resulted in rapid downregulation of survivin protein levels ( Figure 6c) . Also, treatment with lactacystin inhibited downregulation of survivin in cycloheximide-treated cells (data not shown) indicating that survivin is rapidly degraded by the proteasome consistent with previous findings (Zhao et al., 2000) . Interestingly, downregulation of survivin protein expression preceeded reduction of survivin mRNA expression, further indicating that resveratrol decreased survivin levels by both transcriptional and post-transcriptional mechanisms.
Since the role of survivin in regulating apoptosis sensitivity of tumor cells has been controversially discussed and may vary between different cell types (Altieri, 2002) , we tested the effect of downregulation of survivin on sensitivity for drug-induced apoptosis in SHEP neuroblastoma cells using survivin antisense oligonucleotides. Importantly, downregulation of survivin expression by survivin antisense oligonucleotides sensitized SHEP neuroblastoma cells for drug-induced apoptosis (Figure 6d and e) . Furthermore, we used SHEP neuroblastoma cells stably transfected with survivin cDNA (data not shown). Overexpression of Figure 6 Downregulation of survivin by resveratrol sensitizes for drug-induced apoptosis. (a) Effect of resveratrol on survivin mRNA expression. SHEP neuroblastoma cells were treated with 30 mM resveratrol for 0-48 h and assessed for survivin mRNA expression by RT-PCR using primers, which detect survivin and its isoforms survivin-2B and survivin-DEx3 (Mahotka et al., 1999) . GAPDH mRNA expression was used to control for equal gel loading. (b) Effect of proteasome inhibitor on survivin expression. SHEP neuroblastoma cells were treated with 30 mM resveratrol and/or 20 mM of the proteasome inhibitor lactacystin for 24 h and assessed for survivin protein expression by Western blot analysis. Expression of b-actin was used to control for equal gel loading. (c) Effect of protein synthesis inhibitor on survivin expression. SHEP neuroblastoma cells were treated with 1 mg/ml cycloheximide (CHX) for 0-12 h and assessed for survivin protein expression by Western blot analysis. Expression of bactin was used to control for equal gel loading. (d, e) Effect of survivin antisense oligonucleotides on drug-induced apoptosis. SHEP neuroblastoma cells were treated for 24 h with 600 nM survivin antisense (survivin-AS) or mismatched (survivin-MM) oligonucleotides and assessed for survivin protein expression by Western blot analysis (d) or for apoptosis after treatment for 24 h with 0.1 mg/ml doxorubicin, 3 mg/ml VP16 or 1 mg/ml AraC (e). Apoptosis was determined by FACS analysis of propidium iodide-stained DNA. (f, g), Effect of survivin overexpression on resveratrol-mediated sensitization for druginduced apoptosis. SHEP neuroblastoma cells transfected with vector control (f) or survivin cDNA (g) were cultured in medium (white bars) or were pretreated for 24 h with 30 mM resveratrol (black bars), followed by treatment with 1 mg/ml cytarabine (AraC), 0.1 mg/ml doxorubicin or 3 mg/ml VP16 for 24 h. Apoptosis was determined by FACS analysis of propidium iodide-stained DNA survivin-inhibited apoptosis induced by resveratrol and cytyrabine, doxorubicin or VP16 (Figure 6f and g ). These findings indicate that downregulation of survivin by resveratrol may account, at least in part, for the sensitization effect of resveratrol for drug-induced apoptosis.
Resveratrol as chemosensitizer of human cancer cells
To further test the potential of resveratrol as chemosensitizer we extended our studies to various human cancer cell lines. Importantly, treatment with resveratrol, which resulted in reduction of survivin expression (data not shown), sensitized U373MG glioblastoma, MCF7 breast carcinoma cells, LNCaP prostate carcinoma and Reh B-cell leukemia cells, which harbor p53 wild type, as well as Panc1 pancreatic carcinoma or Jurkat T-cell leukemia, which are p53 mutant, for druginduced apoptosis (Figure 7a-f) . Furthermore, we investigated the effect of resveratrol on primary tumor cells derived from metastatic renal cell carcinoma. Interestingly, we found that resveratrol significantly enhanced the effect of doxorubicin-or cisplatinuminduced apoptosis in a dose-dependent manner. These findings indicate that resveratrol is a potent sensitizer for apoptosis induced by anticancer drugs in a variety of human tumor cell lines independent of wild-type p53 status and also in primary tumor cells.
Discussion
Despite aggressive therapies, resistance of many tumors to established treatment regimens still constitutes a major problem in cancer therapy. Thus, attempts to improve the survival of cancer patients largely depend on strategies to target tumor cell resistance. Since induction of apoptosis in target cells is a key mechanism for most antitumor therapies including chemotherapy, g-irradiation, immunotherapy or cytokines, defects in apoptosis programs may cause resistance. Since inhibition of caspases by IAPs occurs in the effector phase of apoptosis, a central point where multiple apoptosis pathways converge, therapeutic modulation of IAPs could target a key mechanism of cancer resistance (Goyal, 2001) .
In recent years, naturally occurring antioxidants present in diet and beverages such as resveratrol have gained considerable attention because of their beneficial effects on health as cancer chemopreventive agents (Park and Pezzuto, 2002) . In search for strategies to overcome resistance of tumor cells, we tested the antitumor activity of resveratrol on human tumor cell lines. Here, we report that resveratrol is a potent sensitizer for anticancer drug-induced apoptosis in a Figure 7 Sensitization for drug-induced apoptosis by resveratrol in human tumor cell lines and primary tumor cells. (a-f) Effect of resveratrol on drug-induced apoptosis in human tumor cell lines. U373MG glioblastoma (a), MCF7 breast carcinoma (b), LNCaP prostate carcinoma (c), Reh B-cell leukemia (d), Jurkat T-cell leukemia (e) and Panc1 pancreatic carcinoma (f) were cultured in medium (white bars) or were pretreated for 24 h with 30 mM resveratrol (black bars), followed by treatment for 24 h with doxorubicin (a), 5-FU (b, c, f) or AraC (d, e) at indicated concentrations. Apoptosis was assessed by FACS analysis of propidium iodide-stained DNA. (g) Effect of resveratrol on drug-induced apoptosis in primary renal cell carcinoma cells. Primary renal cell carcinoma cells were cultured in medium (no Tx) or were pretreated for 24 h with 30 mM resveratrol (Res), followed by treatment for 24 h with 0.6-2 mg/ml doxorubicin (Doxo) or 3-10 mg/ ml cisplatinum (Cis). Cell survival was assessed by MTT assay. Percentage of cell survival was determined as (survival of treated cells Â 100/survival of untreated cells) Sensitization for drug-induced apoptosis by resveratrol S Fulda and K-M Debatin variety of human tumor cell lines through induction of cell cycle arrest and associated survivin depletion in a p53-independent manner.
Sensitization for drug-induced apoptosis by resveratrolmediated cell cycle arrest and associated survivin depletion
The molecular mechanisms of sensitization for druginduced apoptosis by resveratrol involved cell cycle arrest in S phase leading to decreased survivin expression. Likewise, arresting cells at different phases of the cell cycle by chemical inhibitors increased sensitivity towards cytotoxic drugs in S and also in G1 phase of the cell cycle. Resveratrol has previously been shown to induce dose-dependent cell cycle arrest, growth inhibition or apoptosis in several human cancer cell lines (Gusman et al., 2001) . Doses required for resveratrol to induce cell cycle arrest or growth inhibition were usually lower (10-30 mM) than those which induced apoptosis (100-300 mM) (Gusman et al., 2001) . Previous studies on the effects of resveratrol on the cell cycle demonstrated the ability of resveratrol to block the S-G2 transition resulting in a concentration-dependent accumulation of cells in S or G1 phase (Bernhard et al., 2000; Gusman et al., 2001; Kong et al., 2001) . The S phase arrest observed upon treatment with resveratrol has been explained by inhibition of ribonucleotide reductase or DNA polymerase (Gusman et al., 2001) . Our study now considerably extends these earlier observations by showing for the first time that the effect of resveratrol on the cell cycle, for example, cell-cycle arrest in S phase, can be exploited for cancer therapy to render tumor cells more susceptible for death induction by anticancer drugs. Several studies have addressed the issue of cell cycledependent apoptotic sensitivity of tumors (Pucci et al., 2000; Sherr, 2000; Smith et al., 2000) . In the past, most concepts on cell cycle-dependent action of anticancer drugs were focused on the machinery for DNA synthesis and replication (Pucci et al., 2000; Smith et al., 2000) . Because of the cell cycle-specific mode of action of cytotoxic drugs, that directly interfere with DNA synthesis such as antimetabolites, recruitment of cells into S phase, has been used as a strategy to increase drug incorporation into cells. Thus, the cooperative effect of resveratrol and cell cycle-dependent drugs may result from resveratrol-induced cell cycle arrest in S phase, thereby exposing a higher proportion of tumor cell population to the drugs during active DNA replication. Interestingly, however, resveratrol also sensitized for treatment with cell cycle-independent cytotoxic drugs pointing to additional mechanism(s) of synergistic interaction. The central finding that killing of cancer cells by chemotherapy critically depends on activation of apoptosis may provide an alternative explanation. Thus, differential drug sensitivity at distinct phases of the cell cycle may be attributed to cell cycle-dependent expression of apoptosis regulatory proteins such as survivin (Smith et al., 2000) . Cell cycle-dependent transcription of survivin at mitosis has been reported to be regulated by cell-cycle-dependent elements within the survivin promotor (Altieri, 2002) . Also, cell cycle-dependent changes in survivin protein stability have been described (Altieri, 2002) . We found that resveratrol-mediated cell cycle arrest sensitized for drug-induced apoptosis by downregulating survivin expression through transcriptional and post-transcriptional mechanisms. Interestingly, resveratrol treatment did not affect the levels of other IAPs (XIAP, cIAP1, cIAP2) emphasizing the specific effect of resveratrol on cell cycle and survivin expression. Although the role of survivin in apoptosis inhibition has been well established in various systems (Altieri, 2002) , the question as to whether survivin functions in cytoprotection or in the regulation of cell division has also been controversialy discussed and may vary between different cell types. Our findings showing that downregulation of survivin expression using antisense oligonucleotides sensitized for drug-induced apoptosis support the notion that survivin was involved in modulating apoptosis sensitivity in the cell lines studied. Thus, downregulation of survivin through resveratrolinduced cell cycle arrest may provide a molecular link between resveratrol-induced cell-cycle arrest and sensitization for both cell cycle-dependent and cell cycleindependent cytotoxic drugs.
The ability of resveratrol as a single agent to induce apoptosis was relatively low compared to its strong antiproliferative effect at equimolar concentrations indicating that the cytostatic activity of resveratrol is stronger than its cytotoxic activity. Importantly, the combination of resveratrol as 'sensitizer' together with cytotoxic drugs as 'inducers' cooperated to trigger apoptosis. Thus, the potential of resveratrol for anticancer therapy may largely reside in its ability to sensitize tumor cells for death induction, that is to render tumor cells more susceptible for death induction or even to overcome resistance. Clinically, resistance to apoptosis is a major cause of primary or acquired nonresponsiveness of cancer cells leading to treatment failure. Thus, our findings may have therapeutic implications for the following reasons.
First, we identified the chemopreventive compound resveratrol, previously considered to act predominantly as antioxidant, as a novel therapeutic to target survivin expression in cancers. Several studies provided evidence that survivin targeting is a viable anticancer approach to potently trigger apoptosis in vitro and also in vivo (Altieri, 2002) . Second, resveratrol may even be used as chemosensitizer in tumors, in which the tumor suppressor gene p53 is impaired. p53 is mutated or inactivated in the majority of human cancers, which has been associated with chemoresistance both in vitro and in vivo (Wallace-Brodeur and Lowe, 1999; Vousden and Lu, 2002) . Third, our studies showed the broad applicability of resveratrol as sensitizer for cytotoxic therapies. Resveratrol sensitized a variety of human cancer cell lines for apoptosis induced by different anticancer drugs. Interestingly, in addition to sensitize neuroblastoma cells for anticancer drugs commonly used in the clinic for treatment of this tumor such as doxorubicin, VP16, taxol or actinomycin D, resveratrol also sensitized neuroblastoma cells for cytarabine or methotrexate. Increased cytarabine toxicity on neuroblastoma cells has recently been reported in combination with cyclopentyl cytosine, an inhibitor of CTP synthetase (Bierau et al., 2003) , indicating that cytarabine may be effective against neuroblastoma in some combination regimens. The clinical implications of our studies will also depend on whether or not resveratrol can be given safely to humans at doses high enough to achieve pharmacologically active levels. Thus, in terms of a clinical perspective, the combined sensitizer (resveratrol)/inducer (cytotoxic drugs) strategy may be a novel approach to enhance the efficacy of anticancer therapy in a variety of human cancers.
Materials and methods

Cell culture
SHEP neuroblastoma, U373MG malignant glioma, Panc1 pancreatic carcinoma, MCF7 breast carcinoma, LNCaP prostate carcinoma, Jurkat T-cell leukemia, Reh B-cell leukemia cells or primary renal cell carcinoma cells were maintained in RPMI 1640 medium (Life Technologies, Inc., Eggenstein, Germany) supplemented with 10% heat-inactivated FCS, 10 mM HEPES (Biochrom, Berlin, Germany) and 2 mM L-glutamine (Biochrom) as previously described . HCT116 carcinoma were maintained in McCoy 5A medium (Life Technologies) supplemented with 10% heatinactivated FCS, 10 mM HEPES and 2 mM L-glutamine. A measure of 0.5 Â 10 5 cells/ml were cultured in 96-, 24-or sixwell plates or in 75 cm 2 flasks (Falcon, Heidelberg, Germany).
Determination of cell count, proliferation, metabolic activity, clonogenic growth and apoptosis Cells were incubated with resveratrol, doxorubicin, VP16, actinomycin D, taxol, methotrexate, cytarabine, 5-FU, cycloheximide, mimosine, thymidine or nocodazole (all from Sigma, Deisenhofen, Germany) at indicated concentrations and indicated times. Proliferation was assessed by 5-bromo-2 0 -deoxyuridine (BrdU) staining according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany), cell count was assessed by cell counter, clonogenic growth after treatment for 7 days was assessed by crystal violet staining, cell survival was determined by MTT assay according to the manufacturer's instructions (Roche Diagnostics) and apoptosis of adherent and detached cells was assessed by annexin V staining (Roche Diagnostics) or by fluorescence-activated cellsorting (FACS) analysis of propidium iodide-stained nuclei as previously described ). Mean and s.d. of triplicates are shown, similar results were obtained in three independent experiments.
Cell cycle analysis
Cell cycle analysis was performed by fluorescence-activated cell-sorting (FACS) analysis of propidium iodide-stained nuclei as previously described . Concomitant analysis of cell cycle and apoptosis was performed by propidium iodide staining and annexin-FITC.
Antisense oligonucleotides
To inhibit survivin expression phosphothiorate antisense oligonucleotides against survivin expression and mismatch control oligonucleotides (Thermo Hybaid, Ulm, Germany) with published sequences were used as previously described (Olie et al., 2000) .
RT-PCR
Expression of survivin mRNA as assessed by RT-PCR using primers survivin-F: 5 0 -GCATGGGTGCCCCGACGTTG-3 0 , survivin-R: 5 0 -GCTCCGGCCAGAGGCCTCAA-3 0 (Thermo Hybaid), which detect survivin and its isoforms survivin-2B and survivin-DEx3 as previously described (Mahotka et al., 1999) . Expression of GAPDH mRNA was used to control for equal gel loading.
Western blot analysis
